These data support the idea that the aging of bone marrow macrophages influences leukemia phenotype and highlight the CXCL13-CXCR5 axis as a potential target for B-ALL therapy. This evidence concerns the gene CXCR5 and precursor B-cell acute lymphoblastic leukemia.